

# World Journal of *Diabetes*

*World J Diabetes* 2024 December 15; 15(12): 2272-2408



**EDITORIAL**

- 2272 What is the optimal dialysis method for diabetic patients with end stage kidney disease?  
*Kheber NN, Nashwan AJ*

**ORIGINAL ARTICLE****Retrospective Study**

- 2276 COVID-19 infection and inactivated vaccination: Impacts on clinical and immunological profiles in Chinese children with type 1 diabetes  
*Xu ZR, Xi L, Wu J, Ni JW, Luo FH, Zhang MY*
- 2285 Sarcopenia-associated factors and their bone mineral density levels in middle-aged and elderly male type 2 diabetes patients  
*Chen DQ, Wu YX, Zhang YX, Yang HL, Huang HH, Lv JY, Xiao Q*
- 2293 Application value of high-pressure-resistant peripherally inserted central catheters in enhanced computer tomography of diabetic patients with malignant tumors  
*Zhang L, Yan HF*

**Prospective Study**

- 2302 Screening and evaluation of diabetic retinopathy *via* a deep learning network model: A prospective study  
*Yao L, Cao CY, Yu GX, Shu XP, Fan XN, Zhang YF*

**Randomized Controlled Trial**

- 2311 Effect of three-week exercise program on muscle strength and joint mobility in patients with diabetic polyneuropathy: Randomized controlled trial  
*Novaković-Bursać S, Talić G, Tomić N, Škrbić R, Soldatovic I*

**Basic Study**

- 2322  $\beta$ -Arrestin-2 enhances endoplasmic reticulum stress-induced glomerular endothelial cell injury by activating transcription factor 6 in diabetic nephropathy  
*Liu J, Song XY, Li XT, Yang M, Wang F, Han Y, Jiang Y, Lei YX, Jiang M, Zhang W, Tang DQ*
- 2338 Shikonin protects mitochondria through the NFAT5/AMPK pathway for the treatment of diabetic wounds  
*Cen LS, Cao Y, Zhou YM, Guo J, Xue JW*

**CASE REPORT**

- 2353 Intact fish skin graft a new hope for the treatment of diabetic foot ulcers: A case report  
*Jugnet AC, Benard T, Lequint C, Bobony E, Pieheiro AR, Winther T, Penfornis A, Dardari D*

- 2360 Peroxisome proliferator-activated receptor gamma mutation in familial partial lipodystrophy type three: A case report and review of literature

*Wu CJ, Liu H, Tu LJ, Hu JY*

**LETTER TO THE EDITOR**

- 2370 Tenziglipitin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies

*Cheng CY, Hao WR, Liu JC, Cheng TH*

- 2376 Intersection of the glymphatic system and diabetes: Navigating a new frontier

*Rao AG, Nashwan AJ*

- 2380 Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management

*Zhang KX, Kan CX, Wang YQ, Hou NN, Sun XD*

- 2384 Relevance of macrophages in the wound healing process among individuals afflicted with diabetic foot ulcers

*Chen LH, Ran XW*

- 2387 Promise of the gut microbiota in prevention and traditional Chinese medicine treatment of diabetic peripheral neuropathy

*Cao YH, Zhou YM, Wang SY, Guo J, Cen LS*

- 2394 Role of intestinal glucagon-like peptide-1 in impaired counter-regulatory responses to hypoglycemia

*Dodamani MH, Hatwal J, Batta A*

- 2399 Mesenchymal stem cell-derived extracellular vesicles: A promising therapeutic strategy in diabetic osteoporosis

*Yang YJ, Chen XE, Zhou XC, Liang FX*

- 2404 Insights into glymphatic system dysfunction and glucose continuum

*Velikova T, Vasilev G*

**ABOUT COVER**

Editorial Board Member of *World Journal of Diabetes*, José Carlos Tatmatsu-Rocha, PhD, Professor, Medicine School, Department of Physical Therapy, Federal University of Ceara-UFC, Fortaleza 2853, Ceará, Brazil. [tatmatsu@ufc.br](mailto:tatmatsu@ufc.br)

**AIMS AND SCOPE**

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJD* mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

**INDEXING/ABSTRACTING**

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJD* as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Zi-Hang Xu, Production Department Director: Xu Guo, Cover Editor: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Diabetes*

**ISSN**

ISSN 1948-9358 (online)

**LAUNCH DATE**

June 15, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Lu Cai, Md. Shahidul Islam, Michael Horowitz

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-9358/editorialboard.htm>

**PUBLICATION DATE**

December 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies

Chun-Yao Cheng, Wen-Rui Hao, Ju-Chi Liu, Tzu-Hung Cheng

**Specialty type:** Endocrinology and metabolism

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade B

**Novelty:** Grade B

**Creativity or Innovation:** Grade B

**Scientific Significance:** Grade B

**P-Reviewer:** Yao JY

**Received:** March 11, 2024

**Revised:** September 27, 2024

**Accepted:** October 29, 2024

**Published online:** December 15, 2024

**Processing time:** 251 Days and 4 Hours



**Chun-Yao Cheng**, Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan

**Wen-Rui Hao, Ju-Chi Liu**, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan

**Wen-Rui Hao, Ju-Chi Liu**, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11002, Taiwan

**Tzu-Hung Cheng**, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404333, Taiwan

**Co-first authors:** Chun-Yao Cheng and Wen-Rui Hao.

**Corresponding author:** Tzu-Hung Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404333, Taiwan. [thcheng@mail.cmu.edu.tw](mailto:thcheng@mail.cmu.edu.tw)

### Abstract

This article provides commentary on the article by Zhang *et al.* In this original research, Zhang *et al.* investigated the therapeutic potential of teneligliptin for diabetic cardiomyopathy (DCM), which was mediated by targeting the NOD-like receptor protein 3 (NLRP3) inflammasome. Through the use of both *in vivo* and *in vitro* models, the study demonstrated that teneligliptin alleviates cardiac hypertrophy, reduces myocardial injury, and mitigates the inflammatory responses associated with DCM. These findings suggest that teneligliptin's cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation, positioning it as a promising therapeutic option for managing DCM in diabetic patients.

**Key Words:** Diabetic cardiomyopathy; Teneligliptin; Nucleotide-binding oligomerization domain-like receptor 3 inflammasome; Inflammasome inhibition

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Teneeligliptin can mitigate diabetic cardiomyopathy (DCM) by inhibiting NOD-like receptor protein 3 inflammasome activation and upregulating AMP-activated protein kinase signaling. This study provides insights into the molecular mechanisms underlying the beneficial effects of teneeligliptin for the treatment of DCM.

**Citation:** Cheng CY, Hao WR, Liu JC, Cheng TH. Teneeligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies. *World J Diabetes* 2024; 15(12): 2370-2375

**URL:** <https://www.wjgnet.com/1948-9358/full/v15/i12/2370.htm>

**DOI:** <https://dx.doi.org/10.4239/wjd.v15.i12.2370>

## TO THE EDITOR

Diabetic cardiomyopathy (DCM) is a severe complication of diabetes mellitus (DM); DCM is characterized by structural and functional abnormalities in the myocardium that often lead to heart failure[1]. The activation of inflammatory pathways, particularly those involving the NOD-like receptor protein 3 (NLRP3) inflammasome, plays a central role in the development of DCM and is closely associated with myocardial damage in patients with diabetes[2]. Teneeligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a promising therapeutic agent for DCM due to its anti-inflammatory and cytoprotective effects[3]. Zhang *et al*[4] demonstrated that teneeligliptin protects against DCM by inhibiting NLRP3 inflammasome activation. Through *in vivo* and *in vitro* models, their study revealed that teneeligliptin reduces cardiac hypertrophy, alleviates myocardial injury, and suppresses inflammatory pathways. In a streptozotocin-induced diabetic mouse model, teneeligliptin considerably improved cardiac function and reduced the levels of myocardial damage markers[4], indicating its potential to address both the inflammatory and structural aspects of DCM. The rising global prevalence of diabetes and its complications, including DCM, indicates the urgent need for effective treatments. Zhang *et al*[4] indicated that targeting the NLRP3 inflammasome, a key mediator of inflammatory responses, is a novel therapeutic strategy. Teneeligliptin, with its dual roles in glycemic control and preventing inflammation, has promising therapeutic potential for DCM[5]. Although these results are encouraging, further research is required to fully elucidate the mechanisms through which teneeligliptin inhibits NLRP3 inflammasome activation in DCM. In addition, clinical trials should be conducted to investigate the long-term efficacy and safety of teneeligliptin in patients with diabetes and cardiomyopathy [6]. Overall, teneeligliptin is a multifaceted therapeutic option that can substantially improve the management of DCM, offering benefits that extend beyond glycemic control to anti-inflammatory and cardioprotective effects[7].

### Pathophysiology of DCM

DCM is a distinct form of heart disease that is directly associated with diabetes, and it is independent of other common cardiovascular risk factors, such as atherosclerosis and hypertension[1]. The diabetic state triggers several metabolic disturbances, including chronic hyperglycemia, insulin resistance, and dyslipidemia, which collectively drive the pathophysiology of DCM. These metabolic abnormalities lead to the increased production of reactive oxygen species (ROS), causing oxidative stress and damage to myocardial cells[2]. This oxidative stress initiates inflammation, a key factor in DCM progression. The persistent activation of the NLRP3 inflammasome, a multiprotein complex that detects cellular stress signals, is a crucial driver of this inflammatory response. Upon activation, the NLRP3 inflammasome promotes the release of proinflammatory cytokines, particularly interleukin (IL)-1 $\beta$  and IL-18[4]. These cytokines further increase inflammation, causing widespread myocardial damage and accelerating the progression toward heart failure. Chronic hyperglycemia and insulin resistance also contribute to structural abnormalities in the myocardium in DCM, such as myocardial fibrosis and hypertrophy[6]. Fibrosis, which is characterized by excessive collagen deposition in the myocardial extracellular matrix, leads to stiffening of the heart tissue and impaired contractility. Hypertrophy, or thickening of the heart muscle, arises as a compensatory response to the increased workload, but it ultimately exacerbates cardiac dysfunction and promotes heart failure. Apoptosis, or programmed cell death, further complicates these problems by reducing the number of functional cardiomyocytes, contributing to the decline in cardiac function[3]. Increased glucose levels and ROS activate apoptotic pathways in cardiomyocytes, worsening myocardial cell loss and overall cardiac performance[3]. The interplay between oxidative stress, inflammation, fibrosis, hypertrophy, and apoptosis leads to the structural and functional decline observed in DCM. The NLRP3 inflammasome remains a key therapeutic target because its inhibition can alleviate the harmful effects of inflammation in DCM. Agents such as teneeligliptin can reduce NLRP3 activation, decrease cytokine levels, and improve cardiac outcomes in diabetic models[4]. By mitigating both inflammation and oxidative stress, these interventions can delay DCM progression and improve patient outcomes.

### NLRP3 inflammasome: A central player in inflammation

The NLRP3 inflammasome plays a critical role in regulating inflammation, particularly in DCM, where its activation substantially accelerates disease progression. As a key sensor of pathogenic signals, the NLRP3 inflammasome is an essential component of the innate immune system. Under diabetic conditions, elevated glucose levels, mitochondrial dysfunction, and advanced glycation end-product accumulation[4] activate the NLRP3 inflammasome[4]. Once activated, the inflammasome mediates the cleavage and release of proinflammatory cytokines, including IL-1 $\beta$  and IL-18, which amplify inflammation and contribute to progressive myocardial damage[2]. Chronic activation of the NLRP3 inflammasome in the diabetic myocardium is closely linked to fibrosis, which is characterized by excessive extracellular matrix

protein deposition; this causes structural remodeling and increased cardiac stiffness[1]. Persistent NLRP3 activity is also associated with pathological changes, including left ventricular hypertrophy, diastolic dysfunction, and eventual heart failure[2]. Inflammation driven by NLRP3 not only accelerates fibrosis but also impairs both systolic and diastolic cardiac functions, worsening the clinical manifestations of DCM[4]. Therapeutic strategies aimed at reducing NLRP3 activation could halt or slow the progression of DCM. Tenzeligliptin inhibits NLRP3 inflammasome activation and reduces inflammation in the diabetic heart[4]. Studies have demonstrated that teneligliptin reduces the release of IL-1 $\beta$  and IL-18, limits fibrosis, and improves both systolic and diastolic functions, indicating its potential cardioprotective effects for managing DCM[5,8]. In summary, the NLRP3 inflammasome forms a crucial link between metabolic disturbances and immune responses in DCM. Its chronic activation drives structural remodeling and functional decline in the heart. Pharmacological interventions targeting NLRP3, such as teneligliptin, offer significant potential for reducing inflammation and protecting against the progression of diabetic heart disease[1,4].

### **Tenzeligliptin as a therapeutic agent**

Tenzeligliptin is widely recognized for its ability to improve glycemic control in type 2 diabetes by enhancing incretin levels, which stimulate insulin secretion and reduce glucagon production[7]. Beyond its glucose-regulating effects, teneligliptin also exerts anti-inflammatory and cardioprotective effects, making it a promising therapeutic agent in DCM [6]. Recent studies have highlighted the role of teneligliptin in mitigating the activation of the NLRP3 inflammasome, a key mediator of inflammation in DCM[4]. Metabolic dysregulation in diabetes triggers NLRP3 inflammasome activation, leading to the release of proinflammatory cytokines, such as IL-1 $\beta$  and IL-18; these cytokines drive chronic inflammation and fibrosis in cardiac tissue, worsening structural remodeling and functional decline[2]. By inhibiting NLRP3 activation, teneligliptin reduces cytokine secretion and limits myocardial damage, effectively alleviating inflammation and preventing fibrosis in the diabetic heart[2,4]. One of the primary mechanisms underlying the cardioprotective effects of teneligliptin is its ability to attenuate cardiac fibrosis, a defining feature of DCM. Fibrosis contributes to the stiffening of the myocardium, leading to left ventricular diastolic dysfunction and eventual heart failure. Through its inhibition of NLRP3-mediated pro-fibrotic signaling pathways, teneligliptin can preserve cardiac structure and function, as demonstrated in preclinical models[4]. Clinical studies, including the TOPLEVEL trial, have further supported the role of teneligliptin in preventing the progression of left ventricular diastolic dysfunction, indicating its potential for protecting the heart in patients with diabetes[6]. In addition to its cardioprotective effects, teneligliptin exhibits broader anti-inflammatory properties. Its inhibition of the NLRP3 inflammasome is associated with decreased pyroptosis, a form of programmed cell death that contributes to tissue injury in DCM[2]. This mechanism highlights the capacity of teneligliptin to protect cardiomyocytes from injury and death, thus maintaining myocardial integrity[2]. Furthermore, the benefits of teneligliptin extend beyond glucose regulation and inflammation. Tenzeligliptin improves endothelial function and vascular health by modulating circulating endothelial progenitor cells, which play a crucial role in vascular repair and maintenance[9]. These findings suggest that teneligliptin provides comprehensive cardiovascular protection for patients with diabetes; thus, teneligliptin addresses multiple pathways involved in the progression of DCM. In summary, teneligliptin is a multifaceted therapeutic option for managing DCM, exerting both glucose-lowering and cardioprotective effects. By inhibiting NLRP3 inflammasome activation, teneligliptin reduces inflammation, limits fibrosis, and prevents further cardiac damage, making it a valuable agent for mitigating the cardiovascular complications associated with diabetes[4,6].

### **Mechanisms of NLRP3 inhibition by teneligliptin**

Tenzeligliptin inhibits NLRP3 inflammasome activation through multiple mechanisms involving oxidative stress and metabolic signaling pathways. A key mechanism involves the ability of teneligliptin to reduce oxidative stress by enhancing mitochondrial function and minimizing mitochondrial damage, a major trigger for NLRP3 activation[4]. Mitochondrial dysfunction results in excessive ROS production, a well-established activator of the NLRP3 inflammasome[2]. By improving mitochondrial health and suppressing ROS generation, teneligliptin directly protects against inflammasome activation. Moreover, teneligliptin modulates the AMP-activated protein kinase (AMPK) signaling pathway, which plays a crucial role in regulating cellular energy balance and suppressing inflammation[1]. The activation of AMPK by teneligliptin further inhibits the NLRP3 inflammasome, enhancing its anti-inflammatory effects[4]. The ability of teneligliptin to exert dual modulatory effects on metabolic and inflammatory pathways makes it particularly effective for combating chronic inflammation associated with DCM. Recent studies have suggested that teneligliptin alleviates endoplasmic reticulum (ER) stress, another known trigger for NLRP3 inflammasome activation[5]. By reducing ER stress, teneligliptin addresses this upstream driver of inflammation, adding to its protective effects against diabetic complications. Collectively, these mechanisms highlight teneligliptin's ability to comprehensively inhibit the activation of the NLRP3 inflammasome, offering a multifaceted approach to managing DCM and mitigating inflammatory damage in metabolic disorders[4,5].

### **Comparison of teneligliptin with other treatments for DCM**

Tenzeligliptin shows considerable promise for the treatment of DCM, which is primarily due to its anti-inflammatory properties. Although all DPP-4 inhibitors are effective for improving glycemic control, teneligliptin has additional cardiovascular benefits, distinguishing it from other agents in its class and from therapies targeting inflammatory pathways. Compared with other DPP-4 inhibitors, teneligliptin demonstrates enhanced cardioprotective effects. Zhang *et al*[4] indicated that teneligliptin mitigates DCM by inhibiting NLRP3 inflammasome activation, reducing inflammation in cardiac tissues. Other DPP-4 inhibitors, such as sitagliptin and saxagliptin, are effective for glycemic control but have not consistently exhibited the same anti-inflammatory effects in DCM. For example, saxagliptin is associated with an increased risk of heart failure in some patients[10], a concern that is less prominent with teneligliptin due to its unique

pharmacological profile. In addition to DPP-4 inhibitors, therapies targeting inflammatory pathways, such as those inhibiting the NLRP3 inflammasome or reducing ER stress, are promising options for managing DCM. The ability of teneeligliptin to inhibit pyroptosis and alleviate ER stress positions it favorably compared with other anti-inflammatory treatments, including empagliflozin, which primarily focuses on glucose control but also exhibits some anti-inflammatory properties[2]. Cardiovascular benefits further differentiate teneeligliptin from other glucose-lowering therapies. Teneeligliptin might improve vascular endothelial function, a critical factor in managing DCM. Akashi *et al*[9] reported that teneeligliptin enhances the activity of endothelial progenitor cells, contributing to improved cardiac outcomes. Other DPP-4 inhibitors, such as alogliptin, have demonstrated less pronounced cardiovascular benefits, predominantly providing glycemic control. When compared with sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as canagliflozin, teneeligliptin offers complementary effects. SGLT-2 inhibitors exert strong effects on weight reduction and cardiovascular risk mitigation, particularly in patients with heart failure. Combining teneeligliptin with SGLT-2 inhibitors may provide additive benefits. Kadowaki *et al*[7] demonstrated that a combination of teneeligliptin and canagliflozin yielded synergistic effects on body weight control and lipid metabolism, highlighting teneeligliptin as an effective adjunct therapy for patients needing both glycemic and cardiovascular management. Despite its advantages, teneeligliptin has limitations. Although it effectively reduces inflammation and supports cardiovascular health, questions remain regarding its long-term efficacy and safety, especially regarding bone health and diabetic nephropathy. Shaik *et al*[8] raised concerns about potential bone health problem with teneeligliptin in combination therapies, which could limit its use in specific patient subgroups. Furthermore, other anti-inflammatory agents may provide broader protection across multiple organs affected by diabetes, such as the kidneys and nervous system, where teneeligliptin's benefits are less well understood. In conclusion, teneeligliptin is a unique DPP-4 inhibitor with enhanced anti-inflammatory and cardioprotective effects. Its ability to inhibit NLRP3 inflammasome activation and reduce ER stress makes it a valuable therapeutic option for patients with DCM. Although teneeligliptin offers significant advantages over other DPP-4 inhibitors and glucose-lowering therapies, its potential in combination therapies and the need for further research to confirm its long-term safety must be considered.

### **Clinical relevance and potential implications**

Zhang *et al*[4] indicated that teneeligliptin mitigates DCM by inhibiting the activation of the NLRP3 inflammasome. Thus, teneeligliptin can address the unmet clinical needs of patients with diabetes. DCM, a leading cause of heart failure in diabetic individuals, has traditionally been managed with therapies aimed primarily at glycemic control and general cardiovascular protection. However, the progression of DCM is affected by inflammation, fibrosis, and mitochondrial dysfunction, which often render conventional treatments inadequate for treating advanced disease stages[1,2]. Teneeligliptin's ability to inhibit NLRP3 inflammasome activation suggest that it is a novel therapeutic strategy that directly targets the inflammatory mechanisms underlying DCM. This may be especially beneficial for patients with advanced DCM, where traditional therapies have limitations for managing inflammation and fibrosis[4]. The progression of DCM is closely linked to chronic inflammation, mitochondrial dysfunction, and pyroptosis, a form of programmed cell death mediated by the NLRP3 inflammasome[2]. By suppressing these detrimental pathways, teneeligliptin offers a more targeted approach that may delay disease progression and improve clinical outcomes. Incorporating teneeligliptin into treatment regimens may enhance patient care by addressing both the metabolic and inflammatory components of DCM. Its effects on mitochondrial function, reduction of oxidative stress, and activation of the AMPK signaling pathway lead to superior clinical outcomes compared with traditional glucose-lowering agents alone[6,8]. This multifaceted mechanism highlights teneeligliptin's potential to be combined with other therapies for a more comprehensive approach to managing the diverse pathophysiological factors contributing to DCM. These findings have significant clinical implications. By targeting the underlying causes of DCM progression, teneeligliptin offers a more tailored therapy that may reduce the need for invasive interventions, such as heart transplantation, or long-term dependence on heart failure medications[4]. However, translating preclinical findings into clinical practice presents challenges, particularly when evaluating the efficacy of treatments such as teneeligliptin for DCM. Although animal models provide valuable insights into disease mechanisms, they often do not fully replicate human pathophysiology, limiting their prediction of clinical outcomes. For example, although teneeligliptin has been shown to reduce inflammation and prevent DCM by inhibiting NLRP3 inflammasome activation in animal models[4], these results may not always translate directly to humans due to species-specific differences in immune responses and metabolic pathways[2]. To bridge this gap, comprehensive clinical trials are needed to confirm teneeligliptin's efficacy and ensure its safety in diabetic patients with DCM. Previous studies, such as the ARISE-HF trial, have provided valuable data on baseline cardiac dysfunction in patients with diabetes[1], offering a foundation for evaluating new treatments in this population. Moreover, trials such as the TOPLEVEL study, which focuses on teneeligliptin's impact on diastolic dysfunction, indicate the importance of rigorously controlled studies for determining long-term benefits and potential adverse effects in humans[6]. Although teneeligliptin shows promise for targeting inflammatory pathways to mitigate DCM, its long-term safety and efficacy across diverse patient populations must be validated. Kadowaki *et al*[3] highlighted the importance of large-scale post-marketing surveillance, which demonstrated the sustained efficacy of teneeligliptin in more than 10000 patients with type 2 diabetes. Such real-world evidence is crucial for understanding the true clinical utility of the drug and identifying any safety concerns that may emerge with prolonged use. In summary, although preclinical findings are encouraging, translating them into clinical practice requires well-designed, large-scale trials that account for the complexity of human physiology and the multifactorial nature of diseases like DCM. These trials are essential to ensuring that teneeligliptin can safely and effectively benefit diabetic patients, especially those with complications like DCM.

The safety profile of teneeligliptin, as demonstrated in extensive post-marketing surveillance, indicates its potential as a long-term therapeutic option for patients with type 2 DM (T2DM) and cardiovascular complications[3]. Its safety across various patient subgroups, especially those with DCM and other comorbidities should be explored. Teneeligliptin's safety in patients with cardiovascular complications is particularly significant for individuals with DCM. Research, including

that of Zhang *et al*[4], highlights the role of teneligliptin in mitigating DCM progression through the inhibition of the NLRP3 inflammasome, a critical mediator of inflammation and cardiac damage. This anti-inflammatory effect offers a dual advantage for patients managing both T2DM and cardiovascular conditions. The ARISE-HF trial's baseline findings emphasize the complex relationship between diabetes and heart failure, further highlighting the need for therapies such as teneligliptin that may positively affect cardiac outcomes[1]. In addition to its cardiovascular benefits, teneligliptin's safety in combination with other antidiabetic agents has been well-explored. The TOPLEVEL trial, for instance, demonstrates its role in controlling progressive diastolic dysfunction when used alongside standard treatments[6]. Similarly, Kadowaki *et al*[3] demonstrated teneligliptin's long-term safety in over 10000 Japanese patients, indicating that it can be safely integrated into existing glycemic control regimens without significant risks of severe adverse effects. Nonetheless, patient monitoring remains crucial, particularly when teneligliptin is combined with agents such as SGLT2 inhibitors, which have different mechanisms of action. Combination therapies, such as those with canagliflozin, have shown additive benefits in metabolic control and weight reduction, but the long-term cardiovascular impact of these combinations requires further investigation[7,11]. Despite its broad therapeutic potential, concerns regarding the long-term use of teneligliptin, particularly in different demographic and clinical contexts, remain. For example, potential side effects such as bone health issues have been noted, particularly in studies exploring the combination of metformin and teneligliptin[8]. Although teneligliptin shows promise in improving glycemic control and reducing cardiovascular risks, especially in patients with DCM, ongoing clinical trials are necessary to assess its long-term efficacy and safety across diverse patient subgroups and in combination with other antidiabetic agents.

## CONCLUSION

Zhang *et al*'s study significantly advances the understanding of the role of inflammation in the pathogenesis of DCM and establishes a foundation for future therapeutic research[4]. By highlighting that the activation of the NLRP3 inflammasome and associated inflammatory pathways are involved in the pathogenesis of DCM, this research indicates the critical importance of targeting inflammation to mitigate DCM progression[2,4]. Therapeutic agents such as teneligliptin, which have demonstrated potential for reducing inflammation and improving cardiac function in diabetic conditions[1], is a promising avenue for future clinical applications. These findings offer a valuable framework for the development of new treatments that address both glycemic control and the underlying inflammatory mechanisms contributing to DCM[6, 9].

## FOOTNOTES

**Author contributions:** Cheng CY and Hao WR contribute equally to this study as co-first authors; Cheng CY and Hao WR conceptualized the editorial and provided critical insights into the relevance of the study; Liu JC contributed to the analysis and interpretation of the study's findings; Cheng TH supervised the editorial process and provided overall guidance; all of the authors read and approved the final version of the manuscript to be published.

**Conflict-of-interest statement:** All authors declare having no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country of origin:** Taiwan

**ORCID number:** Tzu-Hurng Cheng 0000-0002-9155-4169.

**S-Editor:** Lin C

**L-Editor:** A

**P-Editor:** Zhao YQ

## REFERENCES

- 1 Januzzi JL, Del Prato S, Rosenstock J, Butler J, Ezekowitz J, Ibrahim NE, Lam CSP, Marwick T, Wilson Tang WH, Liu Y, Mohebi R, Urbinati A, Zannad F, Perfetti R. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. *Cardiovasc Diabetol* 2024; **23**: 49 [PMID: 38302936 DOI: 10.1186/s12933-024-02135-z]
- 2 Wang G, Ma TY, Huang K, Zhong JH, Lu SJ, Li JJ. Role of pyroptosis in diabetic cardiomyopathy: an updated review. *Front Endocrinol (Lausanne)* 2023; **14**: 1322907 [PMID: 38250736 DOI: 10.3389/fendo.2023.1322907]
- 3 Kadowaki T, Haneda M, Ito H, Ueno M, Matsukawa M, Yamakura T, Sasaki K, Kimura M, Iijima H. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. *Expert Opin Pharmacother* 2018; **19**: 83-91 [PMID: 29268035 DOI: 10.1080/14656566.2017.1420165]

- 4 **Zhang GL**, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Tenzigliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. *World J Diabetes* 2024; **15**: 724-734 [PMID: 38680706 DOI: 10.4239/wjd.v15.i4.724]
- 5 **Wang W**, Zhang J. Tenzigliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice. *Aging (Albany NY)* 2023; **16**: 8336-8347 [PMID: 38127000 DOI: 10.18632/aging.205333]
- 6 **Imazu M**, Nakano A, Ito S, Hamasaki T, Kitakaze M; TOPLEVEL investigators and study coordinators. Effects of Tenzigliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design. *Cardiovasc Drugs Ther* 2019; **33**: 363-370 [PMID: 30850916 DOI: 10.1007/s10557-019-06871-3]
- 7 **Kadowaki T**, Inagaki N, Watada H, Sasaki K, Mori-Anai K, Iwasaki T, Teranishi T. Real-World Evidence of Treatment with Tenzigliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. *Adv Ther* 2022; **39**: 1642-1658 [PMID: 35138572 DOI: 10.1007/s12325-021-02038-5]
- 8 **Shaik AR**, Kohli S, Vohora D. Bone effects of metformin monotherapy and its combination with tenzilgliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2024; **213**: 111744 [PMID: 38878869 DOI: 10.1016/j.diabres.2024.111744]
- 9 **Akashi N**, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H. Tenzigliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. *Diabetes Metab Syndr Obes* 2023; **16**: 1043-1054 [PMID: 37077576 DOI: 10.2147/DMSO.S403125]
- 10 **Page RL 2nd**, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. *Circulation* 2016; **134**: e32-e69 [PMID: 27400984 DOI: 10.1161/CIR.0000000000000426]
- 11 **Isogawa M**, Makino H, Son C, Nishimura K, Hirata T, Kasama S, Miyamoto Y, Noguchi M, Kasahara M, Hosoda K. Comparison of canagliflozin and tenzilgliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study. *BMC Endocr Disord* 2024; **24**: 153 [PMID: 39160513 DOI: 10.1186/s12902-024-01690-6]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

